|Over a week ago|
Paysafe announces expanded partnership with Betfred USA Sports » 09:1309/0809/08/21
PSFE, PYPL, MA, GPN, PAYS, SQ, AAPL, V
Paysafe (PSFE) announced…
Paysafe (PSFE) announced an expanded partnership with Betfred USA Sports, the wholly-owned U.S. subsidiary of U.K.-based bookmaker Betfred Group. Building on an existing payments relationship, the deal sees Betfred USA Sports plug into the affiliate marketing software of Income Access, Paysafe's marketing technology and services provider, for the upcoming launch of a multi-state affiliate program. The announcement marks the expansion of a partnership through which Betfred USA Sports currently leverages the Skrill USA digital wallet1 for its Iowa online sportsbook, and credit and debit card payment processing via Paysafe's best-in-breed payment gateway for its online sports-betting brand for the Colorado market. Both online gaming brands were unveiled in September 2020 and followed the launch of respective retail sportsbooks earlier that year. With its market presence and strong brand recognition, Betfred USA Sports is positioned for continued growth in the regulated U.S. iGaming space. The launch, scheduled for later this year, of its Income Access-powered affiliate program will support that objective as the operator will utilize a robust reporting and tracking platform to nurture relationships with marketing partners in both the digital and retail space. The program is set to first launch in Colorado with additional states forthcoming. The Fly notes that other publicly traded payment platforms include: PayPal Holdings (PYPL), Mastercard (MA), Global Payments (GPN), Paysign (PAYS), Square (SQ), Apple (AAPL) and Visa (V).
|Over a month ago|
Paysign upgraded to Buy at DA Davidson on expected accelerated growth » 07:3608/2008/20/21
As previously reported,…
As previously reported, DA Davidson analyst Peter Heckmann upgraded Paysign to Buy from Neutral with an unchanged $3.50 price target. The company should see accelerating growth and expanding margins over the next six quarters as volumes in its two primary businesses have rebounded, the analyst tells investors in a research note. The decline in Plasma collection volumes will prove to be temporary, Heckmann adds, stating that the operators of collection centers should continue to raise the compensation per donation to encourage donors to return given the importance of Plasma to the medical field.
Paysign upgraded to Buy from Neutral at DA Davidson » 06:3808/1908/19/21
DA Davidson analyst Peter…
DA Davidson analyst Peter Heckmann upgraded Paysign to Buy from Neutral.
Ladenburg upgrades Paysign to Buy, views pullback as 'attractive opportunity' » 06:5008/1208/12/21
As previously reported,…
As previously reported, Ladenburg analyst Jon Hickman upgraded Paysign to Buy from Neutral with a price target of $3.75, up from $3.50. Q2 revenues in line with his model and up slightly year-over-year were driven by improving traffic at Plasma centers as the U.S. economy recovers from the pandemic, said Hickman, who is estimating 2021 revenue of $30.5M and modeling for a 30% increase for 2022. Given the recent decline in the share price, he sees "an attractive opportunity for growth investors," Hickman said.
Paysign upgraded to Buy from Neutral at Ladenburg » 06:4608/1208/12/21
Ladenburg analyst Jon…
Ladenburg analyst Jon Hickman upgraded Paysign to Buy from Neutral with a $3.75 price target.
Paysign backs FY21 revenue view $29M-$32M, consensus $30.57M » 16:1308/1008/10/21
Jeff Baker, Paysign CFO,…
Jeff Baker, Paysign CFO, said: "While the second quarter continued to be impacted by COVID-19 and government stimulus measures as expected, we did see improving trends as we moved through the quarter. Preliminary indications are that the improving trends will continue as long as the U.S. does not enter widespread lockdown conditions and the government does not provide additional stimulus checks to individuals. More importantly, we continue to believe that our business will benefit in the fourth quarter as unemployment subsidies for the entire country are scheduled to end in early September. For the full year 2021, we continue to forecast total revenue to be in the range of $29.0 million to $32.0 million, reflecting growth of 20% to 32%. We are raising our adjusted EBITDA forecast to be in the range of $0.75 million to $1.90 million due to the better-than-expected results this quarter and higher gross profit margin expectations given operating leverage in our model as plasma volumes recover and we add more pharma programs. We are raising our gross profit margin forecast by 150 basis points to 46.5%, which is an increase of 790 basis points over 2020. Operating expenses are expected to increase modestly between $18.0 million to $18.5 million, or 2.0% to 4.9%."
Paysign reports Q2 EPS (2c), consensus (1c) » 16:1208/1008/10/21
Reports Q2 revenue…
Reports Q2 revenue $6.65M, consensus $6.82M. "We are pleased to report a sequential improvement in our revenues and operating results for the quarter. Throughout the quarter we saw month-over-month improvements in our financial results as pandemic-related stimulus began to phase out, thus providing an incentive for individuals to supplement their income by donating plasma. This trend has continued in July despite the recent U.S. Customs and Border Protection decision affecting Mexican citizens' ability to receive compensation for donating plasma, which only impacted revenue on about 7% of our plasma centers. We continue to focus on diversifying our business and investing for sustained long-term growth. With the renewal of a major pharmaceutical hub customer and their copay programs and the addition of five new pharmaceutical copay programs that are expected to launch between now and the end of 2021, we are excited to continue to advance our capabilities and value in the patient affordability space," said Mark Newcomer, Paysign CEO.
|Over a quarter ago|
Paysign upgraded to Neutral on expected revenue recovery at Ladenburg » 06:5105/1205/12/21
As previously reported,…
As previously reported, Ladenburg analyst Jon Hickman upgraded Paysign to Neutral from Sell with an unchanged price target of $3.50 after the company reported Q1 result and provided guidance for for 2021 and 2022 that points to an expected revenue recovery. Given his updated estimates for 2021 and 2022, and the recent decline in the share price, he thinks a Neutral rating is now appropriate, the analyst explained.
Paysign upgraded to Neutral from Sell at Ladenburg » 06:4105/1205/12/21
Ladenburg analyst Jon…
Ladenburg analyst Jon Hickman upgraded Paysign to Neutral from Sell with a $3.50 price target.
PaySign sees FY21 revenue $29M-$32M, consensus $37.13M » 16:1105/1105/11/21
"While the first…
"While the first quarter continued to be impacted by COVID-19 and government stimulus measures, we believe those factors will begin to abate during the second half of the year and return us to growth in revenues and adjusted EBITDA both sequentially and year-over-year," said Jeff Baker, Paysign CFO. "For the full year 2021, we expect total revenue to be in the range of $29.0 million to $32.0 million, reflecting growth of 20% to 32%, and adjusted EBITDA to be in the range of $0.35 million to $1.90 million. Gross profit margins are expected to be approximately 45.0%, or an increase of 640 basis points over 2020. Operating expenses are expected to increase modestly to $18.0 million to $18.5 million, or 2.0% to 4.9%." Baker concluded, "This outlook presumes that the second-quarter results are slightly better than the first-quarter results and that we begin to see a recovery in the business in the third quarter when unemployment subsidies are scheduled to end in early September. With a non-COVID-19-impacted fourth quarter, we estimate our plasma revenue could reach $27.5 million for the full year 2021 and increase by an additional $10.0 million in 2022."